Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Alemu Birara Zemariam, Yabibal Berie Tadesse & Abebe Tarekegn Kassaw. (2023) Prevalence and Patterns of Adverse Drug Events Among Adult Patients with Human Immune Virus Infection on Dolutegravir-Based Antiretroviral Drug Regimens in Amhara Comprehensive Specialized Hospitals, Northwest Ethiopia: A Multicenter Retrospective Follow-Up Study. HIV/AIDS - Research and Palliative Care 15, pages 271-278.
Read now
Read now
Eden Abetu Mehari, Esileman Abdela Muche, Kedir Abdela Gonete & Kirubel Biruk Shiferaw. (2021) Treatment Satisfaction and Its Associated Factors of Dolutegravir Based Regimen in a Resource Limited Setting. Patient Preference and Adherence 15, pages 1177-1185.
Read now
Read now
Maria del Mar Gutierrez, Mª Gracia Mateo, Noemí Corbacho, Francesc Vidal & Pere Domingo. (2019) Drug-drug interactions when treating HIV-related metabolic disorders. Expert Opinion on Drug Metabolism & Toxicology 15:10, pages 787-802.
Read now
Read now
Stefano Bonora, Andrea Calcagno, Alice Trentalange & Giovanni Di Perri. (2016) Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults. Expert Opinion on Pharmacotherapy 17:3, pages 409-419.
Read now
Read now
Pauline Bollen, Peter Reiss, Jonathan Schapiro & David Burger. (2015) Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection. Expert Opinion on Drug Safety 14:9, pages 1457-1472.
Read now
Read now
María Gracia Mateo, María del Mar Gutierrez, Francesc Vidal & Pere Domingo. (2014) An update on the pharmacological strategies in the treatment of HIV-1-associated adipose redistribution syndromes. Expert Opinion on Pharmacotherapy 15:12, pages 1749-1760.
Read now
Read now
Articles from other publishers (12)
Ronald J. Ellis, María J. Marquine, Marcus Kaul, Jerel Adam Fields & Johannes C. M. Schlachetzki. (2023) Mechanisms underlying HIV-associated cognitive impairment and emerging therapies for its management. Nature Reviews Neurology 19:11, pages 668-687.
Crossref
Crossref
Ahmed Badat & Karishma Lowton. (2022) Case study: New onset of neuropsychiatric symptoms following switching to a dolutegravir regimen. South African Journal of Psychiatry 28.
Crossref
Crossref
Mostafa Shokoohi, Meenakshi Gupta, Fred Crouzat, Graham Smith, Colin Kovacs, Jason Brunetta, Benny Chang, David Knox, Megan Acsai, Barry Merkley, Kevin Giolma, David Fletcher & Mona Loutfy. (2021) Changes in renal and metabolic indices after switching from tenofovir disoproxil fumarate– to tenofovir alafenamide–containing ART among individuals with HIV in Canada: A retrospective study. International Journal of STD & AIDS 32:9, pages 861-871.
Crossref
Crossref
Tyler Lanman, Scott Letendre, Qing Ma, Anne Bang & Ronald Ellis. (2019) CNS Neurotoxicity of Antiretrovirals. Journal of Neuroimmune Pharmacology 16:1, pages 130-143.
Crossref
Crossref
Zhan-Lian Huang, Da-Biao Chen, Zhi-Liang Gao & Bing-Liang Lin. (2020) Enhancing current human immunodeficiency virus/hepatitis B and human immunodeficiency virus/hepatitis C virus co-infection management. Chinese Medical Journal 133:23, pages 2890-2891.
Crossref
Crossref
Orlanda Q Goh, Donn J Colby, Suteeraporn Pinyakorn, Carlo Sacdalan, Eugène Kroon, Phillip Chan, Nitiya Chomchey, Ratchapong Kanaprach, Peeriya Prueksakaew, Duanghathai Suttichom, Rapee Trichavaroj, Serena Spudich, Merlin L Robb, Praphan Phanuphak, Nittaya Phanuphak & Jintanat Ananworanich. (2019)
Switch to dolutegravir is well tolerated in Thais with
HIV
infection
. Journal of the International AIDS Society 22:7.
Crossref
Crossref
Ricky Hsu, Jennifer Fusco, Cassidy Henegar, Karam Mounzer, Michael Wohlfeiler, Vani Vannappagari, Michael Aboud, Lloyd Curtis & Gregory Fusco. (2018) Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the Observational Pharmaco-Epidemiology Research and Analysis database. Therapeutic Advances in Drug Safety 9:12, pages 675-686.
Crossref
Crossref
I.l.i.a.n.a. Alexoudi, A.l.e.x.a.n.d.r.a. Katsarou, V.a.s.s.i.l.e.i.o.s. Paparizos, K.o.n.s.t.a.n.t.i.n.o. Oikonomou, S.o.f.i.a. Kourkounti, G.e.o.r.g.i.a. Augerinou & C.h.r.i.s.t.i.n.a. Antoniou. (2018) Dermatological conditions associated with HIV medication in a cohort of Greek patients initiating antiretroviral therapy: 1988–2013. Journal of Virus Eradication 4:1, pages 26-29.
Crossref
Crossref
Alexandra Ozanne, Pierre Duffau, Frédéric-Antoine Dauchy, Claire Rigothier, Cécile Terrien, Estibaliz Lazaro, Charles Cazanave, Sylvie Lawson-Ayayi, Fabrice Bonnet, Patrick Blanco, Linda Wittkop & Isabelle Pellegrin. (2017) Activation, senescence and inflammation markers in HIV patients. AIDS 31:8, pages 1119-1128.
Crossref
Crossref
Anna Fettiplace, Chris Stainsby, Alan Winston, Naomi Givens, Sarah Puccini, Vani Vannappagari, Ricky Hsu, Jennifer Fusco, Romina Quercia, Michael Aboud & Lloyd Curtis. (2017) Psychiatric Symptoms in Patients Receiving Dolutegravir. JAIDS Journal of Acquired Immune Deficiency Syndromes 74:4, pages 423-431.
Crossref
Crossref
Pere Domingo, Javier Espinet & Francesc Vidal. (2017) ART regimes and fat: the healing hand wielding the sword. The Lancet HIV 4:1, pages e2-e3.
Crossref
Crossref
Sreekumar Othumpangat, John D. Noti & Sidhartha D Ray. 2015. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions
329
348
.